JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 1. P. 65–71
A.S. Balkanov, E.A. Stepanova
The Modern Concept of Using Radiation Therapy for Cancer of the Oral Cavity and the Oropharyngeal Area
M. F. Vladimirsky Moscow Regional Research and Clinical Institute. Moscow, Russia
Е-mail:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
In the world, there is a rise of cancer incidence, including cancer of the head and neck. The incidence cancer of the head and neck is 4.8 cases per 100 000 population. Oral and oropharyngeal cancers are the most frequently forms cancer of the head and neck – 4,8–27 % of all cancer with this location. Among the causes of oral and oropharyngeal cancer noted alcohol abuse, tobacco and infection with human papilloma virus (HPV-16). Mortality from oral and oropharyngeal cancer is on 8 rank among patients with all tumors. Now when deciding about treatment of oral and oropharyngeal cancer is applied a new classification АJCC8th, the main differences from the previous version are the inclusion of data on the depth of tumor invasion and the presence of extranodal growth of lymphogenic metastasis.
The chemoradiotherapy to a total dose 60–74 Gy is the most common treatment used in oral and oropharyngeal cancer. When planning irradiation, both the tumor itself (or its residual component) and lymphogenic metastases or lymph nodes with a high risk of metastatic lesions are included in the target volume. The most commonly used chemotherapy drug is cisplatin. The duration of life of patients is significantly influenced by the stage of the tumor process. So 5-year relapse-free survival among patients with oral cancer is 91 % at T1–2, 83 % – at T3 and 12 % – at T4. During the first 5 years after completion of treatment, the probability of locoregional recurrence in patients with oropharyngeal cancer is much shorter in infected HPV-16 – 28.9 % and 54.9 %, respectively.
The effective multimodal treatment of oral and oropharyngeal cancer can be only if the evaluation of the tumor process under the current classification, comply with the requirements of treatment standards and clinical guidelines as well as take into account the latest achievements of the relevant field of medical science.
Key words: oral cancer, oropharyngeal cancer, new classification, radiation therapy, local relapse, life expectancy
For citation: Balkanov AS, Stepanova EA. The Modern Concept of Using Radiation Therapy for Cancer of the Oral Cavity and the Oropharyngeal Area. Medical Radiology and Radiation Safety. 2020;65(1):65-0. (In Russ.).
DOI: 10.12737/1024-6177-2020-65-1-65-71
Список литературы / References
- Тorre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar; 65(2):87-108. DOI: 10.3322/caac.21262.
- Taziki MH, Fazel A, Salamat F, Sedaghat SM, Ashaari M, Poustchi H, et al. Epidemiology of Head and Neck Cancers in Northern Iran: A 10-Year Trend Study From Golestan Province. Arch Iran Med. 2018 Sep 1;21(9):406-11.
- Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 2014 May; 26(2):123-41. DOI: 10.1016/j.coms.2014.01.001.
- Naghavi AO, Strom TJ, Ahmed KA, et al. Management of Oropharyngeal Cancer in the HPV Era. Cancer Control. 2016;23(3):197-207.
- Kostev K, Lasrich M, Schüller L, Diogo I, Sesterhenn A, Jacob L. Diagnoses of suspected cancer in otolaryngology practices in Germany. Mol Clin Oncol. 2018 Oct; 9(4):459-63. DOI: 10.3892/mco.2018.1694.
- Stanford-Moore G, Bradshaw PT, Weissler MC, Zevallos JP, Brennan P, Anantharaman D, et al. Interaction between known risk factors for head and neck cancer and socioeconomic status: the Carolina Head and Neck Cancer Study. Cancer Causes Control. 2018 Sep;29(9):863-73. DOI: 10.1007/s10552-018-1062-8.
- Wong YF, Yusof MM, Wan Ishak WZ, Alip A, Phua VC. Treatment outcome for head and neck squamous cell carcinoma in a developing country: University Malaya Medical Centre, Malaysia from 2003-2010. Asian Pac J Cancer Prev. 2015;16(7):2903-8.
- Subramaniam N, Thankappan K, Anand A, Balasubramanian D, Iyer S. Implementing American Joint Committee on Cancer 8th edition for head-and-neck cancer in India: Context, feasibility, and practicality. Indian J Cancer. 2018 Jan-Mar;55(1):4-8. DOI: 10.4103/ijc.IJC_475_17.
- Richardson PA, Kansara S3, Chen GG, Sabichi A, Sikora AG, Parke RB, et al. Treatment patterns in veterans with laryngeal and oropharyngeal cancer and impact on survival. Laryngoscope Investig Otolaryngol. 2018 Aug 9;3(4):275-82. DOI: 10.1002/lio2.170.
- D’Сruz A, Lin T, Anand AK, Atmakusuma D, Calaguas MJ, Chitapanarux I, et al. Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. Oral Oncol. 2013 Sep;49(9):872-7. DOI: 10.1016/j.oraloncology.2013.05.010.
- Zhu Y, Zhou C, He Q. Radiation therapy’s efficacy on tongue cancer: a population-based survival analysis. Onco Targets Ther. 2018 Oct 23;11:7271-6. DOI: 10.2147/OTT.S169231.
- Pollom EL, Chin AL, Lee NY, Tsai CJ. Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients. Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):758-66. DOI: 10.1016/j.ijrobp.2017.01.224.
- Subramaniam N, Balasubramanian D, Murthy S, Limbachiya S, Thankappan K, Iyer S. Adverse pathologic features in early oral squamous cell carcinoma and the role of postoperative radiotherapy-a review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jul;124(1):24-31. DOI: 10.1016/j.oooo.2017.03.002.
- Baxi SS, O’Neill C, Sherman EJ, Atoria CL, Lee NY, Pfister DG, Elkin EB. Trends in Chemoradiation Use in Elderly Patients with Head and Neck Cancer: Changing treatment patterns with cetuximab. Head Neck. 2016 Apr; 38(Suppl 1): E165–E171. DOI: 10.1002/hed.23961
- Parsons JT, Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002 Jun 1;94(11):2967-80.
- Moncharmont C, Vallard A, Guy JB, Prades JM, Rancoule C, Magné N. Real-life efficacy of volumetric modulated arc therapy in head and neck squamous cell carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2017 May; 134(3):165-9. DOI: 10.1016/j.anorl.2016.12.005.
- Spencer CR, Gay HA, Haughey BH, Nussenbaum B, Adkins DR, Wildes TM, et al. Eliminating radiotherapy to the contralateral retropharyngeal and high-level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life. Cancer. 2014 Dec 15;120(24):3994-4002. DOI: 10.1002/cncr.28938.
- Mohamed ASR, Bahig H, Aristophanous M, Blanchard P, Kamal M, Ding Y, et al. Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. Clin Transl Radiat Oncol. 2018 May 5;11:11-8. DOI: 10.1016/j.ctro.2018.04.005.
- Vivek RS, Baludavid M, Mohanram R, Chitra, Amanullah, Vijayalakshmi, et al. Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas. J Cancer Res Ther. 2006 Jul-Sep;2(3):90-6.
- Gephardt BJ, Mendenhall CM, Morris CG, KirwanJ, McAfee WJ, Mendenhall WM. Radiotherapy alone or combined with chemotherapy for the treatment of squamous cell carcinoma of the base of the tongue. Am J Clin Oncol. 2014:37(6):535-8. DOI: 10.1097/COC.0b013e31827e5505.
- Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005 May 1; 23(13):3008-15. DOI: 10.1200/JCO.2005.12.060.
- Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M. Differences in survival with surgery and postoperative radiotherapy compared with definitive chemoradiotherapy for oral cavity cancer: A National Cancer Database Analysis. JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):691-9. DOI: 10.1001/jamaoto.2017.0012.
- Rosenthal DI, Mohamed ASR, Garden AS, Morrison WH, El-Naggar AK, Kamal M, et al. Final report of a prospective randomized trial to evaluate the dose-response relationship for postoperative radiation therapy and pathologic risk groups in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2017;98(5):1002-11. DOI: 10.1016/j.ijrobp.2017.02.218.
- O’steen L, Amdur RJ, Morris CG, Hitchcock KE, Mendenhall WM. Challenging the requirement to treat the contralateral neck in cases with >4 mm tumor thickness in patients receiving postoperative radiation therapy for squamous cell carcinoma of the oral tongue or floor of mouth. Am J Clin Oncol. 2019 Jan;42(1):89-91. DOI: 10.1097/COC.0000000000000480.
- Muzumder S, Nirmala S, Avinash HU, Kainthaje PB, Sebastian MJ, Raj JM. Early competing deaths in locally advanced head-and-neck cancer. Indian J Palliat Care. 2018 Oct-Dec;24(4):446-50. DOI: 10.4103/IJPC.IJPC_91_18. 26.
- Powrózek T, Mlak R, Brzozowska A, Mazurek M, Gołębiowski P, Małecka-Massalska T. Relationship between TNF-α -1031T/C gene polymorphism, plasma level of TNF-α, and risk of cachexia in head and neck cancer patients. J Cancer Res Clin Oncol. 2018;144(8):1423-34. DOI: 10.1007/s00432-018-2679-4.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 05.06.2019. Accepted for publication: 11.12.2020.